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Objectives: The primary objective of this study is to compare freedom from biochem-
ical failure (FFBF) between stereotactic body radiation therapy (SBRT) and intensity- 
modulated radiation therapy (IMRT) for patients with organ confined prostate cancer 
treated between 2007 through 2012 utilizing the 2015 National Comprehensive Cancer 
Network (NCCN) risk stratification guidelines. A secondary objective is to compare our 
updated toxicity at last follow-up compared with pretreatment with respect to bowel, 
bladder, sexual functioning, and need for invasive procedures between the two groups.
Methods: We retrospectively reviewed 270 consecutive men treated with either SBRT 
(n = 150) or IMRT (n = 120) at a community hospital with two distinct radiation depart-
ments and referral patterns. Charts were reviewed for pretreatment and treatment factors 
including race, age, clinical T stage, initial PSA, Gleason score, use of androgen depri-
vation therapy, treatment with SBRT vs. IMRT, as well as stratification by 2015 NCCN 
guidelines. Kaplan–Meier (KM) methodology was used to estimate FFBF, with statistical 
comparisons accomplished using log rank tests. Multivariable Cox proportional hazard 
modeling was used to establish independent factors prognostic of biochemical failure. 
Descriptive statistics were used to describe toxicity graded by a modified Radiation 
Therapy Oncology Group (RTOG) late radiation morbidity scoring system.
results: Significant prognostic factors in univariate analysis for FFBF included NCCN 
risk groups (p = 0.0032), grade (p = 0.019), and PSA (p = 0.008). There was no signif-
icant difference in FFBF between SBRT vs. IMRT (p = 0.46) with 6-year actuarial FFBF 
of 91.9% for SBRT and 88.9% for IMRT. Multivariable analysis revealed only the NCCN 
risk stratification to be significant predictor for FFBF (p = 0.04). Four-year actuarial FFBF 
by NCCN risk stratification was 100% very low risk, 100% low risk, 96.5% intermediate 
risk, 94.5% high risk, and 72.7% very high risk. There were no grade 3 gastrointestinal 
or genitourinary toxicities for either SBRT or IMRT at last follow-up.
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inTrODUcTiOn
Intensity-modulated radiation therapy (IMRT) has been a stand-
ard radiation modality used in the treatment of organ confined 
prostate cancer. Ten-year actuarial data (median follow-up 
of 8 years) is available for high dose IMRT up to 81 Gy which 
demonstrates high efficacy in preventing biochemical failure 
with acceptable side effect rates (1). Stereotactic body radiation 
therapy (SBRT) has been accepted as an “appropriate alterna-
tive for select patients with low to intermediate risk disease” as 
per the American Society for Radiation Oncology (ASTRO) 
policy update of April 2013 and is also supported by the National 
Comprehensive Cancer Network (NCCN). SBRT publications 
have validated freedom from biochemical failure (FFBF) and side 
effect rates comparable to IMRT (2, 3).
The combination of prostate cancer’s low alpha/beta ratio, 
known benefit of dose escalation, and efficacy/safety of high dose 
rate brachytherapy led to single institutional, multi-institutional, 
and randomized clinical trials of SBRT for the treatment of 
prostate cancer (4, 5). Despite a clear cost savings for SBRT 
compared with IMRT in a recent pooled Medicare database 
analysis, a 7.5% absolute increased risk of genitourinary (GU) 
toxicity at 24 months was associated with SBRT (6). To date, the 
only direct head-to-head comparison between the two modalities 
with respect to FFBF and toxicity in a single database is from 
our institution reporting 5-year propensity score analysis with no 
significant difference between IMRT and SBRT noted (7).
The primary goal of this study is to update FFBF between 
SBRT and IMRT for men with organ confined prostate cancer 
treated between 2007 through 2012 utilizing the 2015 NCCN risk 
stratification guidelines in a larger database from our institution. 
A secondary objective is to confirm prognostic factors in this 
larger data base through multivariable analysis. An additional 
objective is to evaluate toxicity at last follow-up compared with 
pretreatment with respect to bowel, bladder, sexual functioning, 
and need for invasive procedures in our updated database with 
comparisons between IMRT and SBRT.
MaTerials anD MeThODs
Two hundred seventy consecutive men treated for organ confined 
prostate cancer using either SBRT (n = 150) or IMRT (n = 120) 
between 2007 through 2012 were reviewed on this IRB approved 
retrospective study. Patients were treated with SBRT at an outpatient 
radiation facility and IMRT at the community hospital site, both 
under the same license and radiation department but with distinct 
geographic and referral patterns. PSA nadir was defined as the low-
est PSA value following SBRT or IMRT. Biochemical failure was 
assessed using the Phoenix Nadir + 2 definition (8). Toxicity was 
assessed using the Radiation Therapy Oncology Group (RTOG) 
group criteria with modification. If patients required medication 
for treatment of lower urinary tract symptoms before radiation 
or at last follow-up, our modification of the RTOG system placed 
them into grade 2, which is not required in the RTOG late toxic-
ity scoring system. Erectile function (EF) was graded as grade 0: 
no issues achieving erection adequate for intercourse, grade 1: 
erections sufficient for intercourse most of the time but reduced 
from baseline, grade 2: requiring medications for attainment of EF 
adequate for intercourse, and grade 3: erections not sufficient for 
intercourse most of the time despite use of oral medications or can 
achieve erections with implanted device.
Stereotactic body radiation therapy was delivered using the 
Cyberknife system with multi-plan inverse treatment planning and 
motion tracking of internal fiducials. Treatment planning began 
with transrectal or transperineal ultrasound-guided placement 
of four gold fiducials into the prostate. A CT scan was obtained 
10–14  days later to allow inflammation to subside and ensure 
fiducials did not migrate. T2 fast echo MRI was obtained and 
three-dimensionally registered by fiducials to the CT. All patients 
were simulated in the supine position with immobilization, full 
bladder, and empty rectum. The clinical target volume (CTV) was 
the prostate for very low- and low-risk patients, the prostate plus 
the proximal seminal vesicle for most intermediate, high, and very 
high-risk patients. Pelvic lymph nodes were never targeted. Five 
fractions were prescribed to the planning target volume (PTV) that 
consisted of the CTV with a 5-mm margin in all directions except 
3 mm posteriorly. Dose administered was standard throughout 
our center, which was based on in-house protocol and clinical 
trial participation. Initially, our first few patients were treated with 
35 Gy (EQD2 = 85, assuming an alpha/beta of 1.5 for prostate 
cancer), followed by 37.5 Gy (EQD2 = 96.4), and at the time of 
this publication 36.25 Gy (EQD2 = 90.6), which began 2008 when 
we participated in a national protocol. The dosimetric goal was to 
cover at least 95% of the PTV with the prescribed dose normal-
ized to the 75–85% isodose line (dose heterogeneity 17–33%). 
Less than 1 cm3 of rectum received 36 Gy, 50% of the prescribed 
dose could not cross the posterior rectal wall, and <10  cm3 of 
bladder received 37 Gy. These dose constraints were utilized for 
each prostate dose level. The average/median CTV and PTV 
were 56.7/50.1 cc (SD = 25.7 cc) and 97.9/89.9 cc (SD = 37.9 cc), 
respectively. Orthogonal 120-kV X-ray image pairs were obtained 
throughout treatment for use in motion tracking. The real-time 
prostate position was locked-on by the relative fiducial position 
on the X-rays. For those patients with evenly distributed fiducials 
in the prostate quadrants, the prostate’s rotation was also tracked 
and corrections were made in real time.
conclusion: No significant difference in FFBF was found between SBRT and IMRT for 
organ confined prostate cancer in multivariable analysis within this retrospective data 
set. Overall toxicity was low. The 2015 NCCN risk stratification was validated in this 
population and was the only significant factor for FFBF in multivariable analysis.
Keywords: iMrT, sBrT, prostate cancer, nccn guidelines, freedom from biochemical failure, toxicity
TaBle 1 | Patient descriptive statistics.
Pt characteristics sBrT iMrT p-Value*
number of Pts. 150 120
age at diagnosis Years Years <0.0001
Median (IQR) 67 (11.8) 72 (9.2)
Range 44–88 56–89
Pre-tx Psa ng/ml ng/ml 0.1403
Mean (SD) 8.1 (7.8) 10.8 (18.7)
Median (IQR) 6 (3.7) 6.2 (4.5)
Pre-tx Psa number 
of Pts.
Percent number  
of Pts.
Percent 0.2644
<10 ng/mL 122 81.0 92 76.7
10–20 ng/mL 19 13.0 14 11.7






T1c 113 75.3 43 35.8
T2a 20 13.3 22 18.3
>T2a 17 11.3 55 45.8





5–6 83 55.3 34 28.3
7 55 36.7 61 50.8
8+ 12 8.0 25 20.8




Percent number  
of Pts.
Percent <0.0001
Very low 33 22.0 9 7.5
Low 34 22.7 13 10.8
Intermediate 51 34.0 38 31.7
High 25 16.7 48 40.0
Very high 7 4.6 12 10.0





African-American 49 32.7 17 14.2
Caucasian 90 60.0 101 84.2
Other 7 4.7 1 0.8








noADT 109 73 34 28
ADT 41 27 86 72
*Continuous variable p-value computed by t-test. Categorical variable p-value 
computed by fisher exact test.
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For IMRT, the PTV was defined as the prostate with 8 mm 
margin in all directions except 5 mm posteriorly in very low- and 
low-risk patients, prostate plus seminal vesicles with 5/8  mm 
margin for intermediate and some high risk patients, and prostate 
plus seminal vesicles plus true pelvic lymph nodes with 5/8 mm 
margin for most high and very high risk patients. Dose constraints 
to the rectum were defined as V65 < 17% and V40 < 35%, while 
the bladder constraints were V65 <  25% and V40 <  50%. All 
patients were simulated in the supine position with immobiliza-
tion, full bladder, and empty rectum. CT and MRI treatment 
planning was completed with merging of the images for contour-
ing of the prostate. Image guidance was provided by ultrasound 
pretreatment daily, and patients were treated with full bladder 
daily. Usually, five to seven isocentric beams were utilized to treat 
the prostate with 6 MV photons optimized with an inverse opti-
mization algorithm with at least 95% of the prostate receiving the 
prescribed dose. Approximately 28% of men were treated to the 
prostate alone, 28% to the prostate + seminal vesicles, and 44% 
to the true pelvic lymph nodes + seminal vesicles + prostate. The 
majority of patients received 75.6 Gy (EQ2 = 71.3) to the prostate 
in 1.8 Gy per fraction (72 to <75.6 Gy = 16.8%, 75.6 Gy = 60.5%, 
and >75.6 Gy = 22.7%).
Kaplan–Meier (KM) methodology was used to estimate FFBF 
from end of radiation treatment (EOT), with statistical compari-
sons accomplished using log rank tests. Simple Cox proportional 
hazard modeling was used to estimate hazard ratios; multivariable 
modeling was used to establish independent factors prognostic 
of biochemical failure among NCCN risk groups and treatment 
group (IMRT vs. SBRT). Additionally, multivariable modeling 
was performed using Gleason Score, pretreatment PSA, and 
treatment group. Separate multivariable models were examined 
to avoid multicollinearity issues. All analyses were accomplished 
using SAS V9.4 (Cary, NC).
resUlTs
Patient and Treatment characteristics
The median follow-up time for all patients was 50.2 months (mean = 
55.31, range of 4–108  months). The median follow-up time for 
SBRT and IMRT patients was 45.53 and 53.38 months, respectively.
Pretreatment and treatment factors are described in Table 1. 
Patients were assigned retrospectively by risk groups based on 
the 2015 NCCN risk stratification guidelines. More patients had 
PSA < 10, Gleason score 6 or 7, and T1c/T2a clinical stage. The 
median age for IMRT patients was 72 years, whereas the median 
age for SBRT patients was 67 years. There is a statistically signifi-
cant difference in distribution of patient and treatment charac-
teristics by radiation treatment group with regard to age, race, 
T stage, Gleason score, NCCN risk groups, and use of androgen 
deprivation therapy (ADT), but not PSA.
Of those patients treated with SBRT, 80% were treated 
with either 35 or 36.25  Gy considered the “low dose” group, 
whereas 20% were treated with 37.5 Gy considered the “high 
dose” group. Our previous publication described the effect of 
higher SBRT dose on outcome and will not be further discussed 
here (9).
Psa and Biochemical control
Significant prognostic factors in univariate analysis for FFBF 
included initial PSA (p = 0.008), NCCN risk groups (p = 0.003), 
and Gleason score (p = 0.02) (Figures 1–3). No significant dif-
ferences in FFBF were observed by age, T-stage, race or use of 
androgen deprivation.
Four-year actuarial FFBF by NCCN risk stratification was 
100% very low risk, 100% low risk, 96.5% intermediate risk, 
94.5% high risk, and 72.7% very high risk.1 Four-year actuarial 
FFBF rates were 96.7% for PSA < 10, 100% for PSA 10–20 and 
77.9% for PSA > 20. Five-year actuarial FFBF rates stratified by 
1 Only eight patients at risk with very high risk prostate cancer at 4 years.
FigUre 1 | KM curve stratifying FFBF by initial Psa.
FigUre 2 | KM curve stratifying FFBF by 2015 nccn guidelines.
4
Ricco et al. SBRT vs. IMRT for Prostate Cancer
Frontiers in Oncology | www.frontiersin.org August 2016 | Volume 6 | Article 184
FigUre 3 | KM curve stratifying FFBF by gleason score.
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Gleason score were GS ≤ 6 96.5%, GS = 7 91.1%, and GS ≥ 8 
82.4%. Six-year actuarial FFBF was 91.9% for the SBRT group 
and 88.9% for the IMRT group with no significant difference in 
univariate analysis (p = 0.46) (Figure 4; Table 2).
Seven patients treated with SBRT experienced biochemical 
failure, one in the low-risk group, two each in the intermediate, 
high, and very high-risk groups, all from the low dose category. 
Nine patients treated with IMRT experienced biochemical failure, 
two in the intermediate-risk group, four in the high-risk group, 
and three in the very-high risk groups.
Initial multivariable analysis included the NCCN risk groups 
as well as radiation treatment modality (IMRT vs. SBRT). 
Because Gleason score and PSA are a component of the NCCN 
risk groups, a second multivariable analysis included only 
Gleason score, PSA, and radiation treatment modality to avoid 
inappropriate weighing of prognostic factors. Only NCCN risk 
stratification was a significant predictor for FFBR in multivariable 
analysis (p = 0.04).
Toxicity
Five patients (3.3%) experienced acute grade 3 GU toxicities that 
resolved to either grade 1 or grade 2 by last follow-up in the SBRT 
group. Three of the five patients required TURP for resolution of 
acute symptoms, all three received 37.5 Gy.
For the SBRT group at most recent follow-up, GU toxicities 
were grade 2 in 16% compared with 20% grade 2 at baseline before 
treatment. Of the 16% grade 2 patients at last follow-up, 18/24 
were graded as such purely due to a requirement for medication 
for lower urinary tract symptoms. Of the remaining six patients, 
three had mild hematuria with one patient on warfarin and one 
patient on finasteride. Two patients had incontinence, and one 
patient required self-catheterization. There were no late grade 3 
GU toxicities following SBRT at most recent follow-up (Table 2; 
Figure 5).
For the SBRT group at most recent follow-up, gastrointestinal 
(GI) toxicities were grade 2 in 2.7% compared with 1.3% grade 2 
at baseline before treatment. No late grade 3 GI toxicity was 
reported following SBRT.
For the SBRT group at most recent follow-up, EF was grade 2 
(requiring medication for adequate EF) in 35%, compared with 
18.7% at baseline before treatment. Six percent of men at most 
recent follow-up had EF inadequate for intercourse despite 
medication or required penile prosthesis (grade 3) compared with 
1.3% grade 3 at baseline before treatment. Ninety-seven percent 
of men with EF adequate for intercourse at presentation without 
medications (grades 0–1) were still potent either with or without 
medication at last follow-up (grades 0–2) (Table 3; Figure 6).
For the IMRT group at most recent follow-up, GU toxicities 
were grade 2 in 23% compared with 26% grade 2 at baseline before 
treatment. Of the 23% grade 2 patients at last follow-up, 20/27 
were graded as such purely due to a requirement for medication 
for lower urinary tract symptoms. Of the seven remaining IMRT 
patients with grade 2 toxicity, both hematuria cases were con-
founded with use of anticoagulant, with five other grade 2 toxicity 
cases requiring cystoscopy or other forms of invasive diagnostic 
studies. There were no late grade 3 GU toxicities following IMRT, 
FigUre 4 | KM curve stratifying FFBF by treatment type (iMrT vs. sBrT).












All patients n = 270 99.6 99.6 97.7 95.4 92.2
Age ≤69a 99.3 99.3 95.5 94.5 93.2 0.8337
>69a 100.0 100.0 100.0 96.4 91.2
Treatment SBRT 100.0 100.0 98.2 97.1 92.0 0.4608
IMRT 99.2 99.2 97.1 93.6 92.2
Risk group Very low 100.0 100.0 100.0 100.0 100.0 0.0032
Low 100.0 100.0 100.0 100.0 95.7
Int. 100.0 100.0 98.3 96.5 94.2
High 100.0 100.0 96.5 94.5 89.7
Very high 94.4 94.4 87.2 72.7 72.7
Pre-tx PSA <10 100.0 100.0 98.8 96.7 94.6 0.0083
10–20 100.0 100.0 100.0 100.0 86.3
>20 95.5 95.5 83.9 77.9 77.9
T-stage T1c/T2a 100.0 100.0 99.3 97.0 93.0 0.1184
T2B/T2C 100.0 100.0 94.4 92.2 89.8
T3a 83.3 83.3 83.3 83.3 .
Gleason 
score
5–6 100.0 100.0 98.8 98.8 96.5 0.0199
7 100.0 100.0 98.8 96.2 91.1
8+ 97.1 97.1 90.1 82.4 82.4
ADT No ADT 100.0 100.0 98.1 98.1 92.4
































Grade 0 Grade 1 Grade 2 Grade 3
FigUre 5 | gU toxicity.
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before treatment. No late grade 3 GI toxicities were reported 
following IMRT.
For the IMRT group at most recent follow-up, EF was grade 2 
(requiring medication for adequate EF) in 14%, compared with 
12% at baseline before treatment. Sixty-eight percent of men at 
most recent follow-up had EF inadequate for intercourse despite 
medication or required penile prosthesis (grade 3) compared with 
58% grade 3 at baseline before treatment. Approximately 85.7% 
of men with EF adequate for intercourse at presentation without 
which improved from 4.2% at baseline before treatment (Table 3; 
Figure 5).
For the IMRT group at most recent follow-up, GI toxicities 
were grade 2 in 2.5% compared with 1.7% grade 2 at baseline 
TaBle 3 | Baseline profiles (gU, gi, and eF) for sBrT and iMrT and 
toxicity profile at last FU.
gU sBrT n = 150 n = 150 iMrT n = 120 n = 119
grade sBrT baseline gU s/p sBrT gU iMrT baseline gU s/p iMrT gU
0 36.0% 38.7% 29.2% 36.1%
1 44.0% 45.3% 40.8% 41.2%
2 20.0% 16.0% 25.8% 22.7%
3 0.0% 0.0% 4.2% 0.0%
n= 150 150 120 119
gi sBrT n = 150 n = 150 iMrT n = 120 n = 119
grade sBrT baseline gi s/p sBrT gi iMrT baseline gi s/p iMrT gi
0 87.3% 88.7% 93.3% 90.8%
1 11.3% 8.7% 5.0% 6.7%
2 1.3% 2.7% 1.7% 2.5%
3 0.0% 0.0% 0.0% 0.0%
n= 150 150 120 119
eF sBrT n = 150 n = 150 iMrT n = 117 n = 111
grade sBrT baseline eF s/p sBrT eF iMrT baseline eF s/p iMrT eF
0 49.3% 34.0% 17.9% 11.7%
1 30.7% 24.7% 12.0% 7.2%
2 18.7% 35.3% 12.0% 13.5%
3 1.3% 6.0% 58.1% 67.6%
n= 150 150 117 111
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medications were still potent either with or without medication 
at last follow-up (Table 3; Figure 6).
DiscUssiOn
Our study provides an updated comparison of FFBF and toxicity 
of SBRT and IMRT for the treatment of localized prostate cancer. 
To date, one other study has made this comparison, only report-
ing acute/chronic toxicity and cost comparisons between the two 
modalities in a national database (6). Our study offers late toxicity in 
addition to estimating FFBF with median follow-up times approach-
ing 5 years. We also provided FFBF stratified by the 2015 NCCN 
guidelines of five risk groups which is lacking in the literature and 
the only factor significant in multivariate analysis for our study. We 
explored various known pretreatment factors in univariate analysis 
with other exploratory pretreatment factors such as race and age 
which we had not reported in our previous published experience 
(7, 9). We also explored use of hormone therapy as a confounding 
treatment variable in addition to fractionation scheme.
Intensity-modulated radiation therapy continues to be a standard 
radiotherapeutic technique for the definitive treatment of localized 
prostate cancer using a conventionally fractionated approach with 
1.8–2.0 Gy fractions 5 days/week over 8–9 weeks. A decade of data 
supports this fractionation scheme for localized prostate cancer, 
with excellent biochemical control, overall survival, and acceptable 
toxicity (1). Phase 3 clinical trials of IMRT suggested that this new 
technology provided non-inferior control with acceptable acute 
toxicity, based on the rationale that IMRT was an innovation in 
targeting but prescription dose was based on an already proven 
fractionation scheme (10, 11). Because of an improved therapeutic 
ratio, dose escalation trials could be done with improved outcome 
(1, 12–15). Michalski et al. in 2013 reported the first randomized 
data showing a decrease in grade 2 and above GI toxicity from 22% 
with 3D-CRT to 15.1% with IMRT in the 79.2 Gy arm of RTOG 
0126 (p = 0.04). In addition, although not statistically significant, 
grade 3 and above toxicity was reduced from 5 to 2.6% with IMRT 
(16). Updated analysis of this trial showed a decrease in biochemi-
cal failure, distant metastases with high dose 79.2  Gy compared 
with 70.2  Gy; however, no increase in survival was noted at 
10 years with higher time to late grade 3 or greater GI toxicty for the 
79.2Gy arm (17).
While we await results from an ongoing Swedish phase 3 
trial of hypofractionated radiotherapy delivered in >5 fractions 
completed June 2015, there have been four reported phase 3 
clinical trials of hypofractionation in >5 fractions compared with 
conventionally fractionated radiation which show no clinically 
significant difference in rates of efficacy and late toxicity, with 
median follow-up from 51 to 90 months (18–22). A recent non-
inferiority-designed randomized controlled trial concluded no 
difference in efficacy with minimal increase in toxicity with a 
moderate hypofractionated regimen (23).
We also await the results of RTOG 0938, an equivalency study 
of low-risk prostate cancer, randomizing extreme hypofrac-
tionation with 36.25 Gy in 5 fractions compared with moderate 
hypofractionation of 51.6 Gy in 12 fractions. The study was closed 
February 2014 with 255 patients accrued with the primary objec-
tive of equivalence of 1-year health-related quality of life (24). No 
difference in 1-year quality of life or toxicity was recently reported 
in abstract form of this trial (5).
Several recent SBRT publications report non-inferior clinical 
efficacy with minimal toxicity. King et al. reported a prospective 
study including 1100 patients from 8 institutions which included 
135 patients with at least 5-year follow-up. Among these 135, bio-
chemical relapse-free survival rates were 99 and 93% for low- and 
intermediate-risk, with toxicity rates comparable to IMRT (4). 
While clinicians would like to see 10-year follow-up prospective 
randomized clinical trials to assess the efficacy of SBRT in the 
treatment of localized prostate cancer, the studies of SBRT that 
are available show encouraging results with follow-up approach-
ing the single institutional trials of IMRT (1). Single institutions 
and pooled institutions or registries have shown efficacy and 
acute toxicity on par with IMRT (2–4, 25–27). A recent abstract 
FigUre 6 | eF toxicity.
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by Katz reports the longest follow-up and outcome for a group of 
515 men with organ confined prostate cancer stratified by three 
risk groups. With a median follow-up (FU) of 84 months, 9-year 
FFBF of 95% low risk, 89% intermediate risk, and 66% high risk 
groups was reported with 1.9% RTOG grade 3 urinary toxicity 
but no grade 3 GI toxicity (28).
With the 2015 NCCN risk stratification, multiple risk factors 
(which include Gleason score, pretreatment PSA, and clinical 
stage) promote stage migration and more homogeneity within 
groups. There were no biochemical failures for the very low-risk 
group within either SBRT or IMRT questioning the need for 
treatment in this very low-risk group. While biochemical failure 
was experienced in each other NCCN subgroup, the high and 
very high groups were the most at risk. Of interest is that despite 
no adjuvant lymph node treatment in the SBRT group, there was 
no significant difference in FFBR between SBRT or IMRT con-
sistent with Lawton et al. and Amini et al. for high risk prostate 
cancer patients where no survival difference was noted between 
men treated with whole pelvis vs. prostate only conventionally 
fractionated external beam radiation (29, 30).
Stereotactic body radiation therapy seems well suited for pros-
tate cancer for a number of reasons. The combination of prostate 
cancer’s low a/b ratio, demonstrated benefit of dose escalation 
above conventional doses, and efficacy/safety of high dose rate 
brachytherapy hypofractionation would lead one to believe SBRT 
should be at least comparable to IMRT in efficacy and toxicity for 
the treatment of prostate cancer. SBRT also has sparked interest 
due its convenience (duration of 1–2  weeks as compared with 
8–9 weeks of IMRT treatment), non-invasive nature of treatment 
(compared with brachytherapy), and lower cost. Yu et al. recently 
published a study looking at Medicare records between patients 
treated with SBRT and IMRT and found that the mean treatment 
cost was $13,645 for SBRT vs. $21,023 for IMRT, at a time of 
increasing cost conscientiousness in the US (6).
Despite the fact all men were treated in a single hospital system 
within one radiation department, patients treated with SBRT 
and IMRT came from distinct treatment facilities with only one 
radiation platform available at each site with separate referral 
patterns. Low-risk patients were not preferentially selected for 
SBRT (Table 1). SBRT patients came from five different states, 
many self-referred and motivated for treatment with SBRT. IMRT 
patients alternatively came from the region surrounding the com-
munity hospital. Two physicians treated all patients with IMRT, 
while the majority of SBRT patients were treated by four physi-
cians with only one physician treating at both sites. We began a 
prostate IMRT program in 2003 with significant experience by 
2007 when this study began. Alternatively, we began an SBRT 
program in 2007 with early learning curve and more variation in 
treatment regimens in the early years. Of our SBRT patients who 
developed the most severe acute GU toxicity all were from the 
earliest era with higher doses and less experience. A recent dose 
escalation trial for prostate cancer treated with SBRT showed 
acceptable toxicities up to 47.5 Gy over 2.5 weeks (31). Our low 
toxicity in both the SBRT and IMRT groups suggest that there 
may be room for dose escalation with our series as well.
A commonly cited reason preventing widespread use of 
SBRT in localized prostate cancer is that adoption should not 
happen until we have results from randomized controlled phase 
3 trials, due to fears of late toxicity. Yu et  al. recently brought 
this issue to the forefront, with a comparison of SBRT to IMRT 
using Medicare beneficiary data on patients treated from 2008 
to 2011. This study showed an increase in early and late GU 
toxicity with SBRT as compared with IMRT, with the respective 
increase at 6, 12, and 24 months in the rates of GU toxicity of 3% 
(15.6 vs. 12.6%), 3.9% (27.1 vs. 23.2%), and 7.6% (43.9 vs. 36.3%) 
(6). In contrast to the Yu study, we were able to assess baseline 
GU function and GU function status post SBRT and IMRT, in 
addition to grading the severity of GU toxicity. We found no dif-
ference between SBRT and IMRT in grade 2 GI and GU toxicity 
and no grade 3 toxicity after treatment in either group at most 
recent follow-up. Because we coded toxicity at last follow-up, the 
cumulative risk may be underestimated for patients with limited 
follow-up.
The limitations of this study include fewer high and very 
high risk men treated with SBRT and IMRT compared with the 
larger groups of very low-, low-, and intermediate-risk patients 
and limited power for multivariable assessment given the sample 
size and number of events. Another limitation is the uneven 
distribution in use of ADT between radiation treatment groups 
which could affect FFBF in particular for high and very high risk 
patients. Our treatment groups were unbalanced with regard 
to prognostic factors significant in univariate analysis such as 
Gleason Score and NCCN risk group. In multivariable analysis, 
however, only NCCN risk group was significant for FFBF but 
treatment group (IMRT or SBRT) was not significant in univari-
ate or multivariable analysis. It is possible that there are additional 
factors not accounted for which may affect these results which is 
inherent in all retrospective analyses.
We did not routinely perform quality of life measurements 
prior to initiation of radiation with either IMRT or SBRT; how-
ever, we are now routinely obtaining Expanded Prostate Cancer 
Index Composite (EPIC), International Prostate Symptom 
Score (I-PSS), Bowel Health Inventory, and Sexual Health 
Inventory for Men (SHIM) in follow-up. Using patient-reported 
outcomes for RTOG 0126 trial, no difference was noted for the 
79.2 Gy dose level between IMRT and 3-dimensional confor-
mal radiation therapy through 24  months for bladder, bowel 
or erectile function. This study highlights the importance of 
patient reported outcomes as well as toxicity scales such as 
reported by the RTOG (32). The strength of this study is the 
uniform treatment for both IMRT and SBRT in a single hospital 
department with very separate referral patterns which limited 
treatment selection bias analyzed by known prognostic factors 
including stratification by NCCN 2015 guidelines.
In our experience, SBRT is an alternative to IMRT in the 
treatment of localized prostate cancer, with no significant differ-
ence between SBRT and IMRT for FFBF found. In this study, we 
validated the use of the 2015 NCCN guidelines for prostate cancer 
and have provided FFBF estimates using the five risk strata. To the 
best of our knowledge, no previous database describing outcome 
for prostate cancer following radiation has validated the NCCN 
risk strata, which is the only prognostic factor significant in 
multivariable analysis. Comparative effectiveness data are lacking 
for IMRT vs. SBRT for prostate cancer. Our paper contributes to 
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this literature, which is hypothesis generating but awaits direct 
comparison in a randomized trial.
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